Replies to post #26308 on Seelos Therapeutics Inc (SEEL)

[mean gene]

Fispemifene, imo was not a very good deal for Apricus because if it had good results they would not have the funds to market the product themselves. They would have to partner with someone and pay a royalty out of their royalty from the marketing company. Vitaros if approved in the U.S is a much better deal, they do not have to pay royalty out of their royalty unless Alergan opts out and they have to partner to market the product themselves. I wish they would not have taken their focus off Vitaros and not gotten involved with Fispemifene, I think we would not be in the mess we are in with the pps.

[eicoman]

excellent points SL,

[eicoman]

excellent points SL, he is a real salesman, he may care about the retail investor but I agree all the decisions are made for his friends the institution owners and insiders, which begs the question , what is the strategy to get them a return at this point, Fis. was just a hedge for Denner against his RPRX investment, Vitaros was a backup against potential losses on Fis., so they go for the USA approval and sell the company , IMO

in the USA with advertising they can much better create a market for Vitaros, but only with a company large enough to do the advertising consistently

[growtheport]

I don't find it odd SL. All execs are very good at putting on a great public face. They learn it from MBA school and over years of practice.

As for the institutions, I'm not sure. But you can bet they aren't happy with the short term PPS dive. Welcome to the club.

Fis was just another really bad decision by Pascoe and the Board. But they made it long before they acquired the US rights as I recall. So it goes with overpaid people in charge. I've seen that movie once too often.